These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24244665)

  • 1. Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients.
    Mortier V; Dauwe K; Vancoillie L; Staelens D; Van Wanzeele F; Vogelaers D; Vandekerckhove L; Chalmet K; Verhofstede C
    PLoS One; 2013; 8(11):e80259. PubMed ID: 24244665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
    Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pace of Coreceptor Tropism Switch in HIV-1-Infected Individuals after Recent Infection.
    Arif MS; Hunter J; Léda AR; Zukurov JPL; Samer S; Camargo M; Galinskas J; Kallás EG; Komninakis SV; Janini LM; Sucupira MC; Diaz RS
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28659473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.
    Kagan RM; Johnson EP; Siaw M; Biswas P; Chapman DS; Su Z; Platt JL; Pesano RL
    PLoS One; 2012; 7(9):e46334. PubMed ID: 23029482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
    Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
    J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
    Swenson LC; Chui CK; Brumme CJ; Chan D; Woods CK; Mo T; Dong W; Chapman D; Lewis M; Demarest JF; James I; Portsmouth S; Goodrich J; Heera J; Valdez H; Harrigan PR
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6122-30. PubMed ID: 24080655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
    Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
    J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
    Vandekerckhove L; Verhofstede C; Demecheleer E; De Wit S; Florence E; Fransen K; Moutschen M; Mostmans W; Kabeya K; Mackie N; Plum J; Vaira D; Van Baelen K; Vandenbroucke I; Van Eygen V; Van Marck H; Vogelaers D; Geretti AM; Stuyver LJ
    J Antimicrob Chemother; 2011 Feb; 66(2):265-72. PubMed ID: 21196489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
    Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa.
    Matume ND; Tebit DM; Gray LR; Hammarskjold ML; Rekosh D; Bessong PO
    J Clin Virol; 2018 Jun; 103():81-87. PubMed ID: 29661652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
    Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Jensen MA; Thielen A; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    J Infect Dis; 2011 Jan; 203(2):237-45. PubMed ID: 21288824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
    Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods.
    Kalu AW; Telele NF; Aralaguppe SG; Gebre-Selassie S; Fekade D; Marrone G; Sonnerborg A
    Curr HIV Res; 2018; 16(2):113-120. PubMed ID: 29766813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
    McGovern RA; Symons J; Poon AF; Harrigan PR; van Lelyveld SF; Hoepelman AI; van Ham PM; Dong W; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2013 Sep; 68(9):2007-14. PubMed ID: 23677920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of maraviroc.
    Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
    Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile
    Ko D; McLaughlin S; Deng W; Mullins JI; Dragavon J; Harb S; Coombs RW; Frenkel LM
    Viruses; 2024 Mar; 16(4):. PubMed ID: 38675853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.